Shire awards 10,000 euros to ADHD patient groups

13 October 2014

Ireland-based pharma company Shire (LSE: SHP) announced the winners of the 2014 Excellence in ADHD Patient Group Awards to coincide with World Mental Health Day on Friday.

The Excellence in ADHD Patient Group Awards, developed, funded and organized by Shire, recognize exceptional advocacy campaigns aiming to improve the lives of those living with by attention-deficit hyperactivity disorder (ADHD). The awards were announced in June for the company, which makes Vyvanse (lisdexamfetamine dimesylate) and Adderall XR (mixed amphetamine salts) for ADHD, to expand the level of support it gives to ADHD patients. The judges awarded an unrestricted grant of 10,000 euros ($12,600) to ADHD Hellas (Greece), ADHD Association (Denmark) and the Federation of Andalusian ADHD Supporting Organizations (FAHYDA) in recognition of their outstanding work during 2013 to support people affected by ADHD.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >